Brainomix and Boehringer Ingelheim Partner to Enhance Diagnosis and Treatment of Fibrosing Lung Disease

Brainomix, a leader in AI imaging solutions, has entered into a strategic partnership with Boehringer Ingelheim, a German pharmaceutical company, …

Continue ›››

Genentech Ends SHP2 Inhibitor Collaboration with Relay Therapeutics

Genentech, a member of the Roche Group, has decided to terminate its SHP2 inhibitor collaboration with Relay Therapeutics, returning the …

Continue ›››

CytoReason Secures $80 Million to Advance AI Disease Models

Technology-driven biotech startup CytoReason, a developer of computational disease models, has raised $80 million from a consortium of investors, including …

Continue ›››

Evaxion Biotech Showcases Enhanced AI-Immunology™ Capabilities at ISMB 2024

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has presented significant advancements in its AI-Immunology™ platform, specifically focusing on …

Continue ›››

Synchron Integrates Generative AI with Brain-Computer Interface Software

US-based brain-computer interface (BCI) company Synchron has integrated generative AI into its brain implant interface system, enhancing the ability of …

Continue ›››

Beyond Neuralink: The Diverse Landscape of Brain-Computer Interfaces

Brain-Computer Interfaces (BCIs) have captured the public imagination, largely due to high-profile projects like Neuralink from  Elon Musk's, who revealed …

Continue ›››

Oxford Drug Design Validates Novel Oncology Therapeutic Mechanism

Oxford Drug Design, an AI-driven drug discovery company, has achieved successful in vivo validation of its novel oncology therapeutic mechanism …

Continue ›››

Bioptimus Introduces H-optimus-0: An Open-Source AI Model for Pathology

French startup Bioptimus has released H-optimus-0, the largest open-source AI foundation model for pathology. With 1.1 billion parameters, this model …

Continue ›››

A Growing Race to Change Status Quo in the Lucrative NGS Market

Element Biosciences has raised over $277 million in a Series D funding round to further develop and commercialize its DNA …

Continue ›››

Gene-Editing Tool Modifies Gut Bacteria in Living Mice

Researchers have developed a new gene-editing tool capable of modifying bacterial populations within the gut microbiome of living mice. This …

Continue ›››

Lantern Pharma Advances Development of Molecular Diagnostic for Oncology Clinical Trials

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has reached a milestone in the development of a diagnostic tool for …

Continue ›››

Concr Launches VISION Trial Using Digital Twins for Predicting Breast Cancer Outcomes

Concr has initiated the recruitment of patients for the VISION trial, an observational clinical study designed to evaluate Concr's predictive …

Continue ›››